Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Avacta Group Plc

Market Cap 333M 446M 385M 355M 623M 42.42B 633M 4.19B 1.64B 20.65B 1.68B 1.64B 71.5B P/E Ratio 2025
-6x
P/E Ratio 2026 * -10.6x
Enterprise Value 333M 447M 386M 356M 624M 42.46B 633M 4.2B 1.64B 20.67B 1.68B 1.64B 71.57B EV / Sales 2025
37.2x
EV / Sales 2026 * -
Free-Float
95.95%
Yield 2025 *
-
Yield 2026 * -

Last Transcript: Avacta Group Plc

1 day+3.65%
1 week+1.43%
Current month-10.13%
1 month-19.32%
3 months+2.90%
6 months-7.79%
Current year+22.41%
1 week 66.9
Extreme 66.9
73
1 month 66.9
Extreme 66.9
90
Current year 48
Extreme 48
92
1 year 28
Extreme 28
92
3 years 26
Extreme 26
166.98
5 years 26
Extreme 26
262
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 31/03/2024
Director of Finance/CFO 51 21/01/2025
Chief Tech/Sci/R&D Officer - 08/02/2026
Director TitleAgeSince
Director/Board Member 60 02/02/2020
Director/Board Member 71 16/08/2021
Director/Board Member 56 17/03/2022
Date Insider Type Main position Quantity % Market Cap.
01/09/24Sell

Chief Financial Officer

500,000 0.1393%
01/09/24Free

Chief Executive Officer

3,600,000 1.0027%
01/09/24Fiscal year

Chief Financial Officer

500,000 0.1393%
Change 5-day change 1-year change 3-year change Capi.($)
+3.65%+1.43%+100.00%-34.86% 428M
+1.03%+7.52%+54.74%+114.98% 55.58B
+2.72%+3.06%+53.28%+47.85% 43.47B
+1.12%+2.79%-13.71%-17.53% 22.64B
+1.17%+3.85%+1.00%+401.79% 20.96B
+3.81%-4.13%+16.62%-30.70% 15.79B
+0.15%+2.24%+9.06%-39.50% 15.3B
-0.69%+0.82%+27.17%+178.31% 13.45B
+5.27%+6.41%+21.05% - 11.74B
+1.61%+1.17%+90.79%+212.97% 10.96B
Average +1.98%+0.02%+36.00%+92.59% 21.03B
Weighted average by Cap. +1.71%+1.59%+33.86%+101.34%

Financials

2025 2026 *
Net sales 6.25M 8.39M 7.25M 6.68M 11.71M 797M 11.89M 78.84M 30.74M 388M 31.48M 30.81M 1.34B -
Net income -33.95M -45.57M -39.36M -36.27M -63.62M -4.33B -64.61M -428M -167M -2.11B -171M -167M -7.3B -30.5M -40.94M -35.36M -32.58M -57.16M -3.89B -58.04M -385M -150M -1.89B -154M -150M -6.56B
Net Debt 330K 443K 382K 352K 618K 42.08M 628K 4.16M 1.62M 20.48M 1.66M 1.63M 70.91M 26.93M 36.15M 31.23M 28.77M 50.48M 3.44B 51.26M 340M 132M 1.67B 136M 133M 5.79B
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
151
Date Price Change Volume
12/06/26 71.00 p +3.65% 1,440,798
11/06/26 68.50 p 0.00% 1,344,747
10/06/26 68.50 p -2.84% 2,673,151
09/06/26 70.50 p 0.00% 1,421,980
08/06/26 70.50 p -1.40% 2,245,379
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.6850GBP
Average target price
0.8233GBP
Spread / Average Target
+20.19%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVCT Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!